光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-077 光正眼科医院集团股份有限公司 关于下属子公司综合授信及担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司 融机构申请综合授信额度并提供担保的议案》（公告编号：2025-033）。2025 年 5 月 20 日，公司召开 2024 年年度股东大会审议通过了上述议案。 二、进展情况 特别提示： 截至本公告披露日，光正眼科医院集团股份有限公司（以下简称"公司"） 及控股子公司对外担保总额超过最近一期经审计（归母）净资产 100%，均为公 司、控股子公司、全资子公司及其下属公司间互相担保。敬请投资者关注担保风 险。 一、概述 公司于 2025 年 4 月 22 日召开第六届董事会第二次会议和第六届监事会第二 次会议，分别审议通过了《关于 2025 年度向银行等相关金融机构申请综合授信 额度并提供担保的议案》，同意根据公司 2025 年度生产经营计划和发展规划， 为保证公司正常经营的资金需求，公司、公司合并报表范围内的下属控 ...

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-076 光正眼科医院集团股份有限公司 关于下属子公司综合授信及担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 截至本公告披露日，光正眼科医院集团股份有限公司（以下简称"公司"） 及控股子公司对外担保总额超过最近一期经审计（归母）净资产 100%，均为公 司、控股子公司、全资子公司及其下属公司间互相担保。敬请投资者关注担保风 险。 一、概述 公司于 2025 年 4 月 22 日召开第六届董事会第二次会议和第六届监事会第二 次会议，分别审议通过了《关于 2025 年度向银行等相关金融机构申请综合授信 额度并提供担保的议案》，同意根据公司 2025 年度生产经营计划和发展规划， 为保证公司正常经营的资金需求，公司、公司合并报表范围内的下属控股子公司 及孙公司（简称"控股子公司"）2025 年度拟将向银行等相关金融机构申请总 额不超过 6.5 亿元的综合授信（包括但不限于：信用贷款、第三方担保贷款、资 产抵押贷款、银行承兑汇票、银行保函、保理 ...

Investment Rating - The report maintains a "Buy" rating for the medical services industry [7] Core Insights - The medical and biological sector experienced a decline of 1.04% this week, ranking 17th among 31 primary industries [15] - The medical services sub-sector reported a closing value of 6239.94 points, with an increase of 1.67% [28] - The report highlights a shift in policy focus from cost control to quality and efficiency in the medical sector, emphasizing the need for innovation and sustainable practices [4][70] Summary by Sections Industry Performance - The medical services sector's PE (ttm) is 31.74X, with a PB (lf) of 3.20X, showing a slight decrease from the previous week [3][36] - The top-performing companies in the medical services sector include Zhaoyan New Drug (+23.4%) and MediWest (+12.5%), while the underperformers include Guangzheng Eye Hospital (-9.4%) and Lanwei Medical (-8.7%) [2][34] Economic Policy Developments - The Central Economic Work Conference emphasized optimizing drug procurement and deepening medical insurance payment reforms, aiming to enhance the quality and efficiency of the medical industry [4][70] - The introduction of a long-term care insurance system is expected to stimulate the rehabilitation care industry and address aging population needs [11][72] Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and the weight-loss drug supply chain, with specific companies like WuXi AppTec and Haoyuan Pharmaceutical highlighted [13][74] - It also points to potential recovery in profitability for third-party medical testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry [13][75]

Group 1 - The company, Guangzheng Eye Hospital, announced the completion of changes to its registered capital and business type, as well as the acquisition of a new business license [2] - The registered capital has been changed to 513,574,000 yuan [2]

Market Performance - The medical services sector increased by 0.51% on December 8, with Chengdu XianDao leading the gains [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Top Gainers in Medical Services - Chengdu XianDao (688222) closed at 23.20, up 1.75% with a trading volume of 45,700 shares and a turnover of 106 million yuan [1] - Other notable gainers include: - Guangzheng Eye Hospital (002524) at 4.63, up 1.54% [1] - MediXis (688202) at 53.96, up 1.35% [1] - WuXi AppTec (603259) at 91.55, up 1.27% with a significant turnover of 3.33 billion yuan [1] Top Losers in Medical Services - ST Zhongzhu (600568) closed at 2.79, down 2.11% with a trading volume of 614,600 shares and a turnover of 173 million yuan [2] - Other notable losers include: - Haoyuan Pharmaceutical (688131) at 74.35, down 1.50% [2] - Aoyang Health (002172) at 4.20, down 1.41% [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 297 million yuan from institutional investors, while retail investors saw a net inflow of 317 million yuan [2][3] - Notable capital flows include: - WuXi AppTec (603259) with a net outflow of 30.81 million yuan from institutional investors [3] - NuoSiGe (301333) with a net inflow of 11.54 million yuan from institutional investors [3]

光正眼科医院集团股份有限公司 近日，公司完成了关于变更注册资本、变更企业类型的工商变更登记，并取 得了换发的《营业执照》。最新营业执照基本信息如下： 5、注册地址：新疆乌鲁木齐经济技术开发区融合北路 266 号 6、企业类型：其他股份有限公司（上市） 7、成立日期：2001 年 12 月 10 日 8、经营范围：一般项目：各类眼科疾病诊疗，医学验光配镜，眼科医院的 投资,眼科医院经营管理服务,眼科医疗技术的研究;天然气的销售、运输；建筑钢 结构；对外投资；房屋租赁；物业服务；咨询服务。（除依法须经批准的项目外， 凭营业执照依法自主开展经营活动） 证券代码：002524 证券简称：光正眼科 公告编号：2025-075 光正眼科医院集团股份有限公司 关于公司完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 9 月 4 日召 开公司 2025 年度第二次临时股东大会，审议通过了《关于修订<公司章程>的议 案》及《关于工商变更企业类型并修订＜公司章程＞的议案》，具体内 ...

Core Insights - The collaboration between Tongji University Affiliated Tongji Hospital and Guangzheng Ophthalmology has led to the development of innovative glaucoma drainage valves and anterior chamber puncture devices, winning multiple awards at national competitions [1][2] Group 1: Awards and Recognition - The glaucoma treatment patent won first prize and third prize at the 2025 China Medical Device Innovation and Entrepreneurship Competition, and second prize at the 2025 Yangtze River Delta Industrial Innovation Patent Operation Competition [1] - The awarded patents are now entering subsequent research trials and clinical application phases, supported by collaborations and financing from several well-known medical technology companies [2] Group 2: Collaborative Innovation - Guangzheng Ophthalmology has established three major innovation platforms in collaboration with top institutions, focusing on AI ophthalmic diagnostic systems and minimally invasive treatment device development [3] - The recent patent breakthrough in glaucoma treatment reflects the success of Guangzheng Ophthalmology's innovation research system, emphasizing its commitment to driving advancements in ophthalmic medical technology [3] Group 3: Future Directions - Guangzheng Ophthalmology plans to leverage the recent awards to deepen its focus on the "AI + healthcare" sector, enhancing partnerships with academic and research institutions [3] - The company aims to increase investment in cutting-edge fields such as AI diagnosis and gene therapy, integrating innovative results into its medical service network for broader patient benefit [3]

Core Viewpoint - Guangzheng Eye Hospital (002524) reported that as of November 20, 2025, the total number of shareholders is 36,396 [1] Summary by Category - **Company Information** - Guangzheng Eye Hospital has a total of 36,396 shareholders as of the specified date [1]

光正眼科医院集团股份有限公司 光正眼科医院集团股份有限公司 关于 2023 年限制性股票激励计划部分限制性股票回购注销 完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002524 证券简称：光正眼科 公告编号：2025-074 特别提示： 1.光正眼科医院集团股份有限公司（以下简称"公司"）2023 年限制性股 票激励计划（以下简称"本激励计划"）本次回购注销的限制性股票数量为 3,135,500 股，占回购注销前公司总股本的 0.60%。本次回购注销涉及首次授予 252 名激励对象，回购价格为 3.30 元/股，预留授予 3 名激励对象，回购价格为 1.62 元/股。本次回购注销完成后，公司股份总数由 518,467,074 股减少至 515,331,574 股。 2.截至本公告披露日，公司已在中国证券登记结算有限责任公司深圳分公司 办理完成上述限制性股票的回购注销手续。 一、限制性股票激励计划的具体情况 1.2023 年 8 月 23 日，公司第五届董事会第十九次会议审议通过了《关于公 司<2023 年限制性股票激励计划（草案）>及 ...

Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]